Liberi Group is a global life science consultancy firm specializing in partnering and valuation services, with a primary focus on biotech and pharmaceutical companies. Based in the Netherlands, Liberi Group bridges business development opportunities across the EU, the US, and Asia, forming what we describe as a global triangle of innovation and growth. With over a decade of experience assisting biotech companies in maximizing the value of their assets, we provide comprehensive support throughout the licensing process, from identifying potential partners to negotiating and structuring agreements.
As a boutique consultancy, we deliberately take on a limited number of projects at any given time, ensuring each client receives dedicated attention and a strategy tailored to their specific situation. This focused approach is reflected in a client roster that spans multiple continents and therapeutic areas, including Imugene in Australia, NeoX in China, AGV Discovery in France, and MenoGenix in the United States, among others. It is within this context that we are proud to be working with Vivesto to support partnering activities for its Paccal Vet and Cantrixil programs – an engagement we believe is very well timed given the strength of the data the company has generated to date.
Q1: What exactly does Liberi Group do, and why do biotech companies turn to you?
At its core, what we do is solve a very common problem in the biotech world. You can have a genuinely promising asset – strong science, good data, real market potential – and still struggle to find the right partner. That struggle is usually not about the asset itself. It is about time, connections, and knowing how to position the story for the right audience. That is where we come in. We act as an external business development team, handling the full process of partner identification and outreach so that our clients can stay focused on what they do best, the science. We cover everything from out-licensing and co-development to asset valuation, fundraising, and M&A support. Our clients turn to us because they need results, and they need someone who will treat their program with the same level of commitment they do.
Q2: Walk us through how you actually find the right partner, what does that process look like in practice?
Every engagement starts with a deep dive. Before we even sign a contract, we have already reviewed the asset and formed an initial view on where the opportunities lie. Once we are on board, we sit down with the client team, what we call a kick-off, to hear the story firsthand, understand the goals, and align on strategy. From there, we build the materials: the presentation deck, the due diligence package, everything a potential partner needs to take the program seriously. Then we begin outreach, targeted, not scattered. We are not sending emails to a thousand people. We are having real conversations with the right people. And when there is genuine interest, things can move quickly. We have had clients enter confidential reviews within a matter of weeks. The whole approach is built around quality of fit, not volume of activity.
Q3: What is your track record, and what do clients typically say about the experience of working with you?
We have been doing this for over ten years, and the relationships we have built with our clients are something we are genuinely proud of. One of our clients has been with us for almost a decade, and they will tell you that the partnership we built together is a big part of why they are now on a path to commercial success. Another client, AGV Discovery, entered into a partnership with Ipsen, which we supported from the earliest stages – starting with a co-development agreement at lead stage and culminating in a full license following successful preclinical efficacy.. We also supported a client in completing a licensing agreement with Hinova Pharmaceuticals in China, managing every aspect of that process from identification through to signing. Results like that are what we measure ourselves by.
Q4: How wide is your international network, and does it cover the oncology and veterinary medicine space specifically?
Our network is genuinely global, and we invest in keeping it that way. We attend all the major international life science conferences, and beyond that, we travel across the US, Europe and Asia. We believe that real relationships are built in person, not just over email, and that is reflected in how we operate. In terms of therapeutic areas, we work across the board, and we have meaningful experience in oncology as well as in the veterinary medicine space. The fact that Vivesto’s pipeline spans both human and veterinary oncology is actually something we find very compelling from a partnering perspective as it opens up a broader universe of potential partners than a single-focus program typically would.
Q5: Why should Vivesto shareholders feel confident that Liberi Group will deliver?
I think the honest answer is this: we chose to take on this project because we believe in it. We are selective — we do not work with everyone who approaches us, precisely because we want to be able to deliver for the clients we do work with. When we look at Vivesto’s pipeline programs right now, we see positive clinical data, a near-term catalyst timeline, and two assets that together create a genuinely attractive opportunity for international partners in both veterinary and human oncology. Our job is to make sure the right people see that opportunity and that we build the momentum needed to convert interest into serious partnership discussions. We have done it before, for clients in similar situations, and we are committed to doing it for Vivesto.
Bram de Jong
Director Business Development at Liberi Group